2021
Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China
Lu Y, Zhang H, Lu J, Ding Q, Li X, Wang X, Sun D, Tan L, Mu L, Liu J, Feng F, Yang H, Zhao H, Schulz WL, Krumholz HM, Pan X, Li J, Huang C, Dong Z, Jiang B, Guo Z, Zhang Y, Sun J, Liu Y, Ren Z, Meng Y, Wang Z, Xi Y, Xing L, Tian Y, Liu J, Fu Y, Liu T, Sun W, Yan S, Jin L, Zheng Y, Wang J, Yan J, Xu X, Chen Y, Xing X, Zhang L, Zhong W, Fang X, Zhu L, Xu Y, Guo X, Xu C, Zhou G, Fan L, Qi M, Zhu S, Qi J, Li J, Yin L, Liu Q, Geng Q, Feng Y, Wang J, Wen H, Han X, Liu P, Ding X, Xu J, Deng Y, He J, Liu G, Jiang C, Zha S, Yang C, Bai G, Yu Y, Tashi Z, Qiu L, Hu Z, He H, Zhang J, Zhou M, Li X, Zhao J, Ma S, Ma Y, Huang Y, Zhang Y, Li F, Shen J. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China. JAMA Network Open 2021, 4: e2127573. PMID: 34586366, PMCID: PMC8482054, DOI: 10.1001/jamanetworkopen.2021.27573.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseLipid-lowering medicationsPrimary care institutionsPrevalence of dyslipidemiaControl of dyslipidemiaLipoprotein cholesterolCare institutionsControl rateFemale sexCardiovascular diseaseMAIN OUTCOMEHigh riskNonstatin lipid-lowering drugsHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolPrimary health care settingsMajor public health problemLipid lowering medicationsMillion Persons ProjectOverall control rateLDL-C levelsLipid-lowering drugsCross-sectional studyPublic health problemHealth care settings
2020
Stroke Code Presentations, Interventions, and Outcomes Before and During the COVID-19 Pandemic
Jasne AS, Chojecka P, Maran I, Mageid R, Eldokmak M, Zhang Q, Nystrom K, Vlieks K, Askenase M, Petersen N, Falcone GJ, Wira CR, Lleva P, Zeevi N, Narula R, Amin H, Navaratnam D, Loomis C, Hwang DY, Schindler J, Hebert R, Matouk C, Krumholz HM, Spudich S, Sheth KN, Sansing LH, Sharma R. Stroke Code Presentations, Interventions, and Outcomes Before and During the COVID-19 Pandemic. Stroke 2020, 51: 2664-2673. PMID: 32755347, PMCID: PMC7446978, DOI: 10.1161/str.0000000000000347.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBetacoronavirusBrain IschemiaCohort StudiesComorbidityConnecticutCoronary Artery DiseaseCoronavirus InfectionsCOVID-19DyslipidemiasEmergency Medical ServicesEthnicityFemaleHumansHypertensionIncomeInsurance, HealthIntracranial HemorrhagesMaleMedically UninsuredMiddle AgedOutcome and Process Assessment, Health CarePandemicsPneumonia, ViralRetrospective StudiesSARS-CoV-2Severity of Illness IndexStrokeSubstance-Related DisordersTelemedicineThrombectomyThrombolytic TherapyTime-to-TreatmentConceptsComprehensive stroke centerStroke codePatient characteristicsStroke severityStroke code patientsHistory of hypertensionStroke-like symptomsCoronary artery diseaseCoronavirus disease 2019 (COVID-19) pandemicPatient-level dataLower median household incomePublic health initiativesDisease 2019 pandemicCOVID-19 pandemicRace/ethnicityCode patientsHospital presentationPublic health insuranceRankin ScaleStroke centersArtery diseaseReperfusion timeStroke symptomsEarly outcomesConnecticut hospitals
2019
Interplay of Coronary Artery Calcium and Risk Factors for Predicting CVD/CHD Mortality The CAC Consortium
Grandhi GR, Mirbolouk M, Dardari ZA, Al-Mallah MH, Rumberger JA, Shaw LJ, Blankstein R, Miedema MD, Berman DS, Budoff MJ, Krumholz HM, Blaha MJ, Nasir K. Interplay of Coronary Artery Calcium and Risk Factors for Predicting CVD/CHD Mortality The CAC Consortium. JACC Cardiovascular Imaging 2019, 13: 1175-1186. PMID: 31734198, DOI: 10.1016/j.jcmg.2019.08.024.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCause of DeathComputed Tomography AngiographyCoronary AngiographyCoronary Artery DiseaseDiabetes MellitusDyslipidemiasFemaleHeart Disease Risk FactorsHumansHypertensionMaleMiddle AgedMultidetector Computed TomographyPredictive Value of TestsPrevalencePrognosisRetrospective StudiesRisk AssessmentSmokingTime FactorsUnited StatesVascular CalcificationConceptsCoronary artery calciumCoronary heart diseaseRisk factorsCause-specific mortalityRF burdenCause mortalityArtery calciumCAC scoreCVD mortalityAbsence of CACHigher CAC scoresCHD mortality ratesCurrent cigarette smokingCardiovascular disease deathsCAC ConsortiumCAC testingMulticenter cohortCigarette smokingDisease deathsHeart diseasePrognostic informationBaseline riskFamily historyMost deathsMortality rate
2018
Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study
Bittencourt MS, Blankstein R, Blaha MJ, Sandfort V, Agatston AS, Budoff MJ, Blumenthal RS, Krumholz HM, Nasir K. Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study. European Journal Of Preventive Cardiology 2018, 25: 1887-1898. PMID: 30043629, DOI: 10.1177/2047487318788930.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersClinical Decision-MakingCoronary AngiographyCoronary Artery DiseaseDyslipidemiasFemaleHumansHypolipidemic AgentsIncidenceLipidsMaleMiddle AgedPractice Guidelines as TopicPredictive Value of TestsPrognosisProspective StudiesRisk AssessmentRisk FactorsUnited StatesVascular CalcificationConceptsLipid-lowering treatmentCoronary artery calciumLipid-lowering therapyArtery calciumHigher cardiovascular mortalityCardiovascular mortalityUncontrolled groupCoronary Artery Calcium TestingCoronary heart disease eventsEuropean SocietyHeart disease eventsCardiovascular mortality ratesCardiovascular risk assessmentLow-risk groupCardiology recommendationsCardiology guidelinesCardiovascular riskESC recommendationsRisk stratificationMESA participantsCalcium testingRisk groupsGroup 31Lower incidenceMESA studyComparison of Prevalence, Awareness, Treatment, and Control of Cardiovascular Risk Factors in China and the United States
Lu Y, Wang P, Zhou T, Lu J, Spatz ES, Nasir K, Jiang L, Krumholz HM. Comparison of Prevalence, Awareness, Treatment, and Control of Cardiovascular Risk Factors in China and the United States. Journal Of The American Heart Association 2018, 7: e007462. PMID: 29374046, PMCID: PMC5850247, DOI: 10.1161/jaha.117.007462.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsAttitude of Health PersonnelBlood GlucoseBlood PressureBody Mass IndexCardiovascular DiseasesChinaDiabetes MellitusDyslipidemiasFemaleHealth Knowledge, Attitudes, PracticeHealth Status DisparitiesHumansHypertensionHypolipidemic AgentsLipidsLongitudinal StudiesMaleMiddle AgedNutrition SurveysObesityPractice Patterns, Physicians'PrevalencePrognosisRisk AssessmentRisk FactorsTime FactorsUnited StatesWaist CircumferenceConceptsHigher stroke prevalenceCardiovascular risk factorsHigh-sensitivity C-reactive proteinBody mass indexC-reactive proteinRisk factorsBlood pressureWaist circumferenceMass indexStroke prevalenceCardiovascular risk factor profileHigher mean blood pressureControl of hypertensionMean blood pressureBlood pressure levelsRisk factor profileComparison of prevalenceRepresentative population sampleLower ratesDyslipidemia awarenessSevere hypertensionHemoglobin A1cHypertension treatmentControl ratePlasma glucoseNational Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey
Salami JA, Warraich HJ, Valero‐Elizondo J, Spatz ES, Desai NR, Rana JS, Virani SS, Blankstein R, Khera A, Blaha MJ, Blumenthal RS, Katzen BT, Lloyd‐Jones D, Krumholz HM, Nasir K. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. Journal Of The American Heart Association 2018, 7: e007132. PMID: 29358195, PMCID: PMC5850149, DOI: 10.1161/jaha.117.007132.Peer-Reviewed Original ResearchAdultAgedAtherosclerosisDatabases, FactualDrug CostsDrug PrescriptionsDyslipidemiasFemaleHealth Care SurveysHealth ExpendituresHealthcare DisparitiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsLongitudinal StudiesMaleMedically UninsuredMiddle AgedPractice Patterns, Physicians'Racial GroupsRetrospective StudiesRisk FactorsSex FactorsSocioeconomic FactorsTime FactorsTreatment OutcomeUnited States
2014
Impact of Drug Policy on Regional Trends in Ezetimibe Use
Lu L, Krumholz HM, Tu JV, Ross JS, Ko DT, Jackevicius CA. Impact of Drug Policy on Regional Trends in Ezetimibe Use. Circulation Cardiovascular Quality And Outcomes 2014, 7: 589-596. PMID: 24895451, PMCID: PMC4222175, DOI: 10.1161/circoutcomes.114.001023.Peer-Reviewed Original Research
2013
When Choosing Statin Therapy: The Case for Generics
Green JB, Ross JS, Jackevicius CA, Shah ND, Krumholz HM. When Choosing Statin Therapy: The Case for Generics. JAMA Internal Medicine 2013, 173: 229-232. PMID: 23303273, DOI: 10.1001/jamainternmed.2013.1529.Commentaries, Editorials and Letters
2012
Statins: Is It Safe and Effective to Use Generic “Equivalents”?
Jackevicius CA, Tu JV, Krumholz HM. Statins: Is It Safe and Effective to Use Generic “Equivalents”? Canadian Journal Of Cardiology 2012, 29: 408-410. PMID: 23062664, DOI: 10.1016/j.cjca.2012.08.012.Peer-Reviewed Original Research
2008
Use of Recommended Ambulatory Care Services: Is the Veterans Affairs Quality Gap Narrowing?
Ross JS, Keyhani S, Keenan PS, Bernheim SM, Penrod JD, Boockvar KS, Federman AD, Krumholz HM, Siu AL. Use of Recommended Ambulatory Care Services: Is the Veterans Affairs Quality Gap Narrowing? JAMA Internal Medicine 2008, 168: 950-958. PMID: 18474759, DOI: 10.1001/archinte.168.9.950.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAmbulatory CareBehavioral Risk Factor Surveillance SystemBreast NeoplasmsCholesterolColorectal NeoplasmsCounselingDiabetes MellitusDiabetic RetinopathyDisease ManagementDyslipidemiasFemaleHospitals, VeteransHumansInfluenza VaccinesMaleMiddle AgedPneumococcal VaccinesPreventive Health ServicesQuality of Health CareSmoking CessationUnited StatesVeteransConceptsVeterans Affairs Medical CenterAmbulatory care servicesInsured adultsCancer screeningCare servicesBehavior Risk Factor Surveillance SystemRisk Factor Surveillance SystemCardiovascular risk reductionColorectal cancer screeningChronic disease careBreast cancer screeningQuality improvement initiativesQuality of careUS health care systemInfectious disease preventionHealth care systemHealth Care Quality Improvement InitiativeEye examinationSelf-reported useDisease careCancer preventionMellitus managementMedical CenterAmbulatory careService use
2006
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update Endorsed by the National Heart, Lung, and Blood Institute
Smith S, Allen J, Blair S, Bonow R, Brass L, Fonarow G, Grundy S, Hiratzka L, Jones D, Krumholz H, Mosca L, Pasternak R, Pearson T, Pfeffer M, Taubert K. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update Endorsed by the National Heart, Lung, and Blood Institute. Journal Of The American College Of Cardiology 2006, 47: 2130-2139. PMID: 16697342, DOI: 10.1016/j.jacc.2006.04.026.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAtherosclerosisCardiovascular AgentsCoronary Artery DiseaseDiabetes MellitusDyslipidemiasHealth BehaviorHematologic AgentsHumansHypertensionHypolipidemic AgentsInfluenza VaccinesMineralocorticoid Receptor AntagonistsMotor ActivityObesitySmoking Cessation